Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180458 | 0.89 | XDH (0.51) | FYNKDRMAP4K4ABL1BCR | |
| SCHEMBL4199338 | 0.87 | KDR (0.57) | FYNKDREGFRXDHSLC22A12 | |
| SCHEMBL4187560 | 0.84 | SIRT2 (0.51) | FYNKDRMAP4K4NPC1RAB9A | |
| SCHEMBL4190144 | 0.84 | ALDH1A1 (0.47) | L3MBTL1FYNABL1EGFRSRC | |
| SCHEMBL4154769 | 0.82 | PARP1 (0.50) | FYNKDRNPC1ABL1EGFR | |
| SCHEMBL4183159 | 0.81 | FYN (0.55) | FYNABL1BCRXDHSLC22A12 | |
| SCHEMBL4778358 | 0.76 | KDM4E (0.58) | EGFR | |
| SCHEMBL1663227 | 0.76 | L3MBTL1 (0.76) | L3MBTL1NPC1RAB9ALMNATP53BP1 | |
| SCHEMBL4188883 | 0.75 | HDAC2 (0.50) | NPC1RAB9ALMNA | |
| SCHEMBL4153750 | 0.75 | FYN (0.53) | FYNKDRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | L3MBTL1 2877/4885FYN 3292/4885KDR 4228/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | L3MBTL1 2877/4885FYN 3292/4885KDR 4228/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | L3MBTL1 2877/4885FYN 3292/4885KDR 4228/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | L3MBTL1 2937/4885FYN 173/4885KDR 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.